

Genomic profiles of MALT lymphomas: variability across anatomical sites

Ivo Kwee,^{1,2} Paola M. V. Rancoita,^{1,2} Andrea Rinaldi,¹ Andrés J.M. Ferreri,³ Govind Bhagat,⁴ Randy D. Gascoyne,⁵ Vincenzo Canzonieri,⁶ Gianluca Gaidano,⁷ Claudio Doglioni,³ Emanuele Zucca,¹ Maurilio Ponzoni,^{3*} and Francesco Bertoni^{1*}

*co-senior Authors

¹Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; ²Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland; ³Pathology Unit, Medical Oncology Unit and Unit of Lymphoid Malignancies, San Raffaele H Scientific Institute, Milan, Italy; ⁴Institute for Cancer Genetics, Department of Pathology and Cell Biology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA; ⁵Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada; ⁶Division of Pathology, Centro di Riferimento Oncologico, Istituti di Ricovero e Cura a Carattere Scientifico, Aviano (PN) Italy; and ⁷Division of Hematology, Department of Clinical and Experimental Medicine & BRMA, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Citation: Kwee I, Rancoita PMV, Rinaldi A, Ferreri AJM, Bhagat G, Gascoyne RD, Canzonieri V, Gaidano G, Doglioni C, Zucca E, Ponzoni M, and Bertoni F. Genomic profiles of MALT lymphomas: variability across anatomical sites. *Haematologica* 2011;96(07):1064-1066. doi:10.3324/haematol.2011.040402

Online Supplementary Table S1. Frequency of the minimal common regions (MCR) per anatomical site. The P value is calculated comparing the frequency for cases with involvement of the individual anatomical site versus cases without involvement of that specific anatomical site. MCR type is according to Lenz et al.¹³ Core-start and Core-end indicate the start and the end of the MCR core region, defined as the region covered by at least two-thirds of the aberrations in the overlapping group. Mapping data are based on the National Center for Biotechnology Information (NCBI) Human Genome Build 36.

locus	Status	MCR type	Orbital Adnexa	P value	Stomach	P value	Salivary/Parotid/p.value	Thyroid	P value	Lung	P value	mcr.core.start	mcr.core.end
1p21.2	loss	short recurrent abnormality (SRA)	1.9%	0.043	14.3%	0.021	8.3%	1.000	1.000	25.0%	0.069	99970351	101604426
2p25.3	gain	short recurrent abnormality (SRA)	20.4%	0.112	10.7%	0.548	0.0%	0.214	0.611	0.0%	0.600	24049	2465693
2p11.2	gain	short recurrent abnormality (SRA)	0.0%	0.002	17.9%	0.037	16.7%	0.255	0.550	12.5%	0.492	88767363	89912849
3p26.3-q29	gain	long recurrent abnormality (LRA)	29.6%	0.293	21.4%	1.000	16.7%	0.728	0.450	12.5%	0.679	48603	199318155
3p	gain	abnormal chromosome arm (ACA)	31.5%	0.053	17.9%	0.602	8.3%	0.293	0.683	12.5%	1.000	48603	90346746
3q	gain	abnormal chromosome arm (ACA)	29.6%	0.203	17.9%	0.602	16.7%	0.729	0.685	12.5%	1.000	95031169	199318155
3	gain	abnormal whole chromosome (AWC)	29.6%	0.084	17.9%	0.787	8.3%	0.298	0.682	12.5%	1.000	48603	199318155
4p12-p11	loss	short recurrent abnormality (SRA)	9.3%	0.130	28.6%	0.064	25.0%	0.397	0.352	37.5%	0.127	48031374	48758236
4q24	loss	short recurrent abnormality (SRA)	7.4%	1.000	10.7%	0.707	0.0%	0.597	1.000	12.5%	0.536	106516638	106576030
6p25.3-p132	gain	long recurrent abnormality (LRA)	20.4%	0.009	3.6%	0.175	8.3%	1.000	0.596	0.0%	0.594	119769	32979514
6q23.2-q24.2	loss	long recurrent abnormality (LRA)	14.8%	0.581	10.7%	1.000	0.0%	0.358	1.000	12.5%	1.000	134077297	145000503
6q23.2-q23.3	loss	short recurrent abnormality (SRA)	25.9%	0.277	17.9%	0.787	16.7%	1.000	1.000	12.5%	1.000	135101251	139048099
6q23.3	hdel	short recurrent abnormality (SRA)	1.9%	0.629	0.0%	0.557	0.0%	1.000	1.000	25.0%	0.030	138117846	138458773
6q27	gain	short recurrent abnormality (SRA)	18.5%	0.017	0.0%	0.031	8.3%	1.000	0.595	25.0%	0.206	169236122	170655773
6p	gain	abnormal chromosome arm (ACA)	20.4%	0.000	0.0%	0.058	8.3%	1.000	1.000	0.0%	1.000	119769	58835467
7p15.1	gain	short recurrent abnormality (SRA)	7.4%	0.753	10.7%	0.345	0.0%	0.599	0.586	12.5%	0.395	31532863	31550647
7q11.22	gain	short recurrent abnormality (SRA)	11.1%	0.335	3.6%	1.000	0.0%	0.596	0.550	12.5%	0.341	68795203	69353057
11q24.3	gain	short recurrent abnormality (SRA)	9.3%	1.000	14.3%	0.262	0.0%	0.599	0.586	0.0%	1.000	128177160	128327270
11q25	gain	short recurrent abnormality (SRA)	11.1%	0.601	28.6%	0.028	8.3%	1.000	0.604	12.5%	1.000	133857095	134439182
13q32.2	loss	short recurrent abnormality (SRA)	9.3%	0.749	10.7%	0.707	8.3%	1.000	1.000	12.5%	0.536	97030899	97288167
14q11.2	loss	short recurrent abnormality (SRA)	44.4%	0.055	25.0%	0.246	33.3%	1.000	0.717	0.0%	0.048	19336854	22045540
14q32.13	loss	short recurrent abnormality (SRA)	16.7%	0.419	10.7%	0.548	8.3%	1.000	0.335	0.0%	0.600	92831915	93162237
16p13.3	loss	short recurrent abnormality (SRA)	9.3%	1.000	17.9%	0.308	0.0%	0.606	0.044	0.0%	0.591	31010	4073014
17p13.3-p13.1	loss	short recurrent abnormality (SRA)	3.7%	0.299	7.1%	0.312	0.0%	1.000	1.000	12.5%	0.282	2672305	9903073
18p11.32-q23	gain	long recurrent abnormality (LRA)	31.5%	0.089	32.1%	0.449	8.3%	0.290	1.000	12.5%	0.676	210071	76115554
18q23	gain	short recurrent abnormality (SRA)	42.6%	0.006	35.7%	0.814	8.3%	0.108	1.000	12.5%	0.432	75800881	76115554
18p	gain	abnormal chromosome arm (ACA)	25.9%	0.259	28.6%	0.420	8.3%	0.456	1.000	12.5%	1.000	210071	15096727
18q	gain	abnormal chromosome arm (ACA)	27.8%	0.181	28.6%	0.435	8.3%	0.458	1.000	12.5%	0.679	16857220	76115554
18	gain	abnormal whole chromosome (AWC)	25.9%	0.259	28.6%	0.420	8.3%	0.456	1.000	12.5%	1.000	210071	76115554
19q12	loss	short recurrent abnormality (SRA)	1.9%	0.076	14.3%	0.215	0.0%	1.000	0.108	12.5%	0.492	34516147	34782367
21q21.3	loss	short recurrent abnormality (SRA)	1.9%	0.041	14.3%	0.460	8.3%	1.000	0.160	25.0%	0.176	25952343	26021515
21q22.3	loss	short recurrent abnormality (SRA)	0.0%	0.017	10.7%	0.065	0.0%	1.000	1.000	12.5%	0.341	42330907	42531513
21q22.3	gain	short recurrent abnormality (SRA)	5.6%	0.510	17.9%	0.111	0.0%	0.596	0.550	0.0%	1.000	46727421	46894358